Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKNA Ikena Oncology	$1.36 +1.5%	$1.25	$0.97 ▼ $1.94	$65.63M	0.45	118,234 shs	32,868 shs
IPA ImmunoPrecise Antibodies	$1.11	$0.62	$0.27 ▼ $1.16	$50.80M	0.12	2.52 million shs	1.09 million shs
KRON Kronos Bio	$0.88 +1.5%	$0.79	$0.65 ▼ $1.60	$53.72M	1.64	360,698 shs	54,089 shs
PYXS Pyxis Oncology	$1.10 -6.8%	$1.18	$0.83 ▼ $5.39	$68.14M	1.18	736,727 shs	6.61 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKNA Ikena Oncology	0.00%	0.00%	+15.25%	+3.03%	-17.07%
IPA ImmunoPrecise Antibodies	0.00%	+10.45%	+93.31%	+183.16%	+10.45%
KRON Kronos Bio	0.00%	0.00%	+31.05%	+7.32%	-7.57%
PYXS Pyxis Oncology	0.00%	-5.98%	-12.00%	+3.77%	-65.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IKNA Ikena Oncology	3.2654 of 5 stars	3.3	3.0	3.8	1.7	1.3
IPA ImmunoPrecise Antibodies	2.3247 of 5 stars	3.5	3.0	2.7	0.0	0.6
KRON Kronos Bio	3.5843 of 5 stars	3.2	3.0	2.9	4.2	1.3
PYXS Pyxis Oncology	2.0332 of 5 stars	3.4	1.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKNA Ikena Oncology	2.50	Moderate Buy	$3.00	120.59% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	260.36% Upside
KRON Kronos Bio	2.33	Hold	$1.63	84.66% Upside
PYXS Pyxis Oncology	2.80	Moderate Buy	$9.00	718.18% Upside

Current Analyst Ratings Breakdown

Latest IPA, IKNA, PYXS, and KRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKNA Ikena Oncology	$9.16M	7.17	N/A	N/A	$2.61 per share	0.52
IPA ImmunoPrecise Antibodies	$18.16M	2.80	N/A	N/A	$0.93 per share	1.19
KRON Kronos Bio	$9.85M	5.45	N/A	N/A	$1.45 per share	0.61
PYXS Pyxis Oncology	$16.15M	4.22	N/A	N/A	$2.03 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKNA Ikena Oncology	-$49.23M	-$0.86	N/A	N/A	N/A	N/A	-30.59%	-27.55%	8/14/2025 (Estimated)
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-190.76%	-88.87%	-49.26%	7/3/2025 (Estimated)
KRON Kronos Bio	-$86.08M	-$1.07	N/A	N/A	N/A	-701.53%	-64.22%	-47.17%	8/6/2025 (Estimated)
PYXS Pyxis Oncology	-$77.33M	-$1.59	N/A	N/A	N/A	N/A	-57.49%	-45.17%	8/13/2025 (Estimated)

Latest IPA, IKNA, PYXS, and KRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	PYXS Pyxis Oncology	-$0.29	-$0.35	-$0.06	-$0.35	N/A	N/A
5/8/2025	Q1 2025	IKNA Ikena Oncology	-$0.21	-$0.18	+$0.03	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKNA Ikena Oncology	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKNA Ikena Oncology	N/A	13.31	13.31
IPA ImmunoPrecise Antibodies	0.45	2.32	2.11
KRON Kronos Bio	N/A	12.93	12.93
PYXS Pyxis Oncology	N/A	7.75	7.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKNA Ikena Oncology	75.00%
IPA ImmunoPrecise Antibodies	6.70%
KRON Kronos Bio	64.09%
PYXS Pyxis Oncology	39.09%

Insider Ownership

Company	Insider Ownership
IKNA Ikena Oncology	5.94%
IPA ImmunoPrecise Antibodies	6.83%
KRON Kronos Bio	24.40%
PYXS Pyxis Oncology	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKNA Ikena Oncology	70	48.26 million	45.39 million	Not Optionable
IPA ImmunoPrecise Antibodies	80	45.76 million	42.64 million	Not Optionable
KRON Kronos Bio	100	61.05 million	46.16 million	Optionable
PYXS Pyxis Oncology	60	61.95 million	55.38 million	Optionable

IPA, IKNA, PYXS, and KRON Headlines

Recent News About These Companies

Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14

June 19, 2025 | finance.yahoo.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Brokerages

June 16, 2025 | marketbeat.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Deutsche Bank AG

June 5, 2025 | marketbeat.com

Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments

May 30, 2025 | tipranks.com

Millennium Management LLC Has $4.65 Million Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS)

May 30, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)

May 22, 2025 | theglobeandmail.com

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | globenewswire.com

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs

May 8, 2025 | baystreet.ca

Pyxis Oncology reveals promising preclinical data for cancer drug

April 27, 2025 | investing.com

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

April 25, 2025 | globenewswire.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

April 23, 2025 | zacks.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

April 16, 2025 | zacks.com

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

April 2, 2025 | globenewswire.com

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

March 25, 2025 | globenewswire.com

Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)

March 24, 2025 | markets.businessinsider.com

RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

March 20, 2025 | markets.businessinsider.com

Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)

March 18, 2025 | markets.businessinsider.com

Pyxis Oncology (PYXS) Gets a Hold from William Blair

March 18, 2025 | markets.businessinsider.com

Pyxis Oncology Advances Cancer Therapeutics with MICVO

March 18, 2025 | tipranks.com

Pyxis Oncology Reports Promising Phase 1 Data for MICVO in Head and Neck Cancer, Receives FDA Fast Track Designation

March 18, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Broadcom Earnings Preview: AVGO Stock Near Record Highs
By Leo Miller | June 3, 2025
View Broadcom Earnings Preview: AVGO Stock Near Record Highs

IPA, IKNA, PYXS, and KRON Company Descriptions

Ikena Oncology NASDAQ:IKNA

$1.36 +0.02 (+1.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.36 0.00 (0.00%)

As of 06/27/2025 06:04 PM Eastern

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

ImmunoPrecise Antibodies NASDAQ:IPA

$1.11 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.10 -0.02 (-1.35%)

As of 06/27/2025 07:56 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Kronos Bio NASDAQ:KRON

$0.88 +0.01 (+1.49%)

As of 06/20/2025

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Pyxis Oncology NASDAQ:PYXS

$1.10 -0.08 (-6.78%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.16 +0.06 (+5.45%)

As of 06/27/2025 06:56 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time